Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Molecular Pathogenesis of Membranous Nephropathy.

Ronco P, Debiec H.

Annu Rev Pathol. 2019 Oct 17. doi: 10.1146/annurev-pathol-020117-043811. [Epub ahead of print]

PMID:
31622560
2.

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.

PMID:
31340979
3.

Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab.

Georges E, Johanet C, Plaisier E, Debiec H, Ronco P, Dahan K.

Kidney Int Rep. 2019 Mar 13;4(7):1027-1030. doi: 10.1016/j.ekir.2019.03.002. eCollection 2019 Jul. No abstract available.

4.

Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.

Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC, Ronco P.

J Am Soc Nephrol. 2019 Jun;30(6):1123-1136. doi: 10.1681/ASN.2018080852. Epub 2019 May 6.

PMID:
31061139
5.

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.

Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, Ronco P, Debiec H, Lambeau G.

Kidney Int. 2019 Mar;95(3):666-679. doi: 10.1016/j.kint.2018.10.024.

PMID:
30784662
6.

Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.

Dahan K, Johannet C, Esteve E, Plaisier E, Debiec H, Ronco P.

Kidney Int. 2019 Jan;95(1):233-234. doi: 10.1016/j.kint.2018.08.045. No abstract available.

PMID:
30606419
7.

Factor H Autoantibodies and Membranous Nephropathy.

Seikrit C, Ronco P, Debiec H.

N Engl J Med. 2018 Dec 20;379(25):2479-2481. doi: 10.1056/NEJMc1805857. No abstract available.

PMID:
30575481
8.

HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.

Wang HY, Cui Z, Xie LJ, Zhang LJ, Pei ZY, Chen FJ, Qu Z, Huang J, Zhang YM, Wang X, Wang F, Meng LQ, Cheng XY, Liu G, Zhou XJ, Zhang H, Debiec H, Ronco P, Zhao MH.

Kidney Int. 2018 Nov;94(5):974-982. doi: 10.1016/j.kint.2018.06.005. Epub 2018 Aug 30.

PMID:
30173899
9.

Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome.

Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschênes G, Ronco P.

J Am Soc Nephrol. 2018 Jul;29(7):2000-2013. doi: 10.1681/ASN.2017111185. Epub 2018 Jun 14.

10.

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

Dahan K, Gillion V, Johanet C, Debiec H, Ronco P.

Kidney Int Rep. 2017 Nov 3;3(2):498-501. doi: 10.1016/j.ekir.2017.10.013. eCollection 2018 Mar. No abstract available.

11.

Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy.

Berchtold L, Zanetta G, Dahan K, Mihout F, Peltier J, Guerrot D, Brochériou I, Ronco P, Debiec H.

Kidney Int Rep. 2017 Sep 21;3(2):486-491. doi: 10.1016/j.ekir.2017.09.009. eCollection 2018 Mar. No abstract available.

12.

Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.

van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J.

Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019. No abstract available.

PMID:
29571438
13.

Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.

Ritz D, Sani E, Debiec H, Ronco P, Neri D, Fugmann T.

Proteomics. 2018 Jun;18(12):e1700246. doi: 10.1002/pmic.201700246. Epub 2018 Mar 14.

14.

Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.

Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, Esnault VLM, Lambeau G, Ronco P.

J Am Soc Nephrol. 2018 Feb;29(2):401-408. doi: 10.1681/ASN.2017070734. Epub 2017 Nov 7.

15.

Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.

Wang J, Cui Z, Lu J, Probst C, Zhang YM, Wang X, Qu Z, Wang F, Meng LQ, Cheng XY, Liu G, Debiec H, Ronco P, Zhao MH.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1642-1651. doi: 10.2215/CJN.01460217. Epub 2017 Aug 11.

16.

A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.

Ronco P, Debiec H.

Pflugers Arch. 2017 Aug;469(7-8):997-1005. doi: 10.1007/s00424-017-2007-x. Epub 2017 Jun 8. Review.

PMID:
28597189
17.

B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.

Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P.

Kidney Int. 2017 Jul;92(1):227-237. doi: 10.1016/j.kint.2017.01.012. Epub 2017 Mar 15.

PMID:
28318628
18.

Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.

Pourcine F, Dahan K, Mihout F, Cachanado M, Brocheriou I, Debiec H, Ronco P.

PLoS One. 2017 Mar 3;12(3):e0173201. doi: 10.1371/journal.pone.0173201. eCollection 2017.

19.

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group.

J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.

20.

Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.

Guerry MJ, Vanhille P, Ronco P, Debiec H.

Kidney Int. 2016 Jun;89(6):1399. doi: 10.1016/j.kint.2015.11.032. No abstract available.

PMID:
27181779
21.

Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency.

Bally S, Debiec H, Ponard D, Dijoud F, Rendu J, Fauré J, Ronco P, Dumestre-Perard C.

J Am Soc Nephrol. 2016 Dec;27(12):3539-3544. Epub 2016 May 6.

22.

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.

Kimura Y, Miura N, Debiec H, Morita H, Yamada H, Banno S, Ronco P, Imai H.

Clin Exp Nephrol. 2017 Feb;21(1):117-126. doi: 10.1007/s10157-016-1235-2. Epub 2016 Feb 1.

23.

Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy.

Debiec H, Ronco P.

J Am Soc Nephrol. 2016 May;27(5):1275-7. doi: 10.1681/ASN.2015101170. Epub 2015 Dec 11. No abstract available.

24.

Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients.

Ronco P, Debiec H.

Mol Immunol. 2015 Nov;68(1):57-62. doi: 10.1016/j.molimm.2015.07.003. Review.

25.

[Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].

Pozdzik AA, Debiec H, I Brochériou, Husson C, Rorive S, Broeders N, Le Moine A, Ronco P, Nortier J.

Rev Med Brux. 2015 May-Jun;36(3):166-71. Review. French.

PMID:
26372979
26.

Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.

Ronco P, Debiec H.

Lancet. 2015 May 16;385(9981):1983-92. doi: 10.1016/S0140-6736(15)60731-0. Review.

PMID:
26090644
27.

Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy.

Stehlé T, Audard V, Ronco P, Debiec H.

Nephrol Dial Transplant. 2015 Jun;30(6):1047-50. doi: 10.1093/ndt/gfv080. Epub 2015 Apr 2.

PMID:
25839741
28.

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G.

J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.

29.

Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.

Vivarelli M, Emma F, Pellé T, Gerken C, Pedicelli S, Diomedi-Camassei F, Klaus G, Waldegger S, Ronco P, Debiec H.

Kidney Int. 2015 Mar;87(3):602-9. doi: 10.1038/ki.2014.381. Epub 2015 Jan 7.

30.

Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy.

Ronco P, Debiec H.

Nephron Clin Pract. 2014;128(3-4):232-7. doi: 10.1159/000368588. Epub 2014 Nov 11. Review.

31.

Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis.

Baruteau J, Heissat S, Broué P, Collardeau-Frachon S, Bouvier R, Fabre M, Debiec H, Ronco P, Uzan M, Narcy P, Cordier MP, Lachaux A, Lamireau T, Elleau C, Filet JP, Mitanchez D, Dupuy MP, Salaün JF, Odent S, Davison J, Debray D, Guigonis V.

J Pediatr Gastroenterol Nutr. 2014 Nov;59(5):629-35. doi: 10.1097/MPG.0000000000000514.

PMID:
25079484
32.

Immunopathogenesis of membranous nephropathy: an update.

Debiec H, Ronco P.

Semin Immunopathol. 2014 Jul;36(4):381-97. doi: 10.1007/s00281-014-0423-y. Epub 2014 Apr 9. Review.

PMID:
24715030
33.

[Anti-CD 10 maternal-fetal allo-immunisation].

Ronco P, Debiec H.

Bull Acad Natl Med. 2012 Nov;196(8):1613-22; discussion 1622-3. French.

34.

Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy.

Debiec H, Valayannopoulos V, Boyer O, Nöel LH, Callard P, Sarda H, de Lonlay P, Niaudet P, Ronco P.

J Am Soc Nephrol. 2014 Apr;25(4):675-80. doi: 10.1681/ASN.2013030290. Epub 2013 Nov 21.

35.

Circulating antipodocyte antibodies in membranous nephropathy: pathophysiologic and clinical relevance.

Ronco P, Debiec H, Imai H.

Am J Kidney Dis. 2013 Jul;62(1):16-9. doi: 10.1053/j.ajkd.2013.03.016. Epub 2013 May 2. No abstract available.

36.

Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P.

J Am Soc Nephrol. 2013 Mar;24(4):677-83. doi: 10.1681/ASN.2012070730. Epub 2013 Feb 21.

37.

[Pathophysiology of extramembranous glomerulopathies. Fifty years of progress, from laboratory to patient].

Ronco P, Debiec H.

Biol Aujourdhui. 2013;207(4):249-59. doi: 10.1051/jbio/2013025. Epub 2014 Mar 5. Review. French.

PMID:
24594573
38.

Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.

Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H.

Nephrol Dial Transplant. 2013 Jul;28(7):1839-44. doi: 10.1093/ndt/gfs439. Epub 2012 Dec 6.

PMID:
23223223
39.

Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor.

Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, Aucouturier P, Godin M, Ronco P.

J Am Soc Nephrol. 2012 Dec;23(12):1949-54. doi: 10.1681/ASN.2012060577. Epub 2012 Nov 2.

40.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF.

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. Epub 2012 Sep 6.

41.

French retrospective multicentric study of neonatal hemochromatosis: importance of autopsy and autoimmune maternal manifestations.

Collardeau-Frachon S, Heissat S, Bouvier R, Fabre M, Baruteau J, Broue P, Cordier MP, Debray D, Debiec H, Ronco P, Guigonis V.

Pediatr Dev Pathol. 2012 Nov-Dec;15(6):450-70. doi: 10.2350/12-02-1155-OA.1. Epub 2012 Aug 17.

PMID:
22901025
42.

Pathophysiological lessons from rare associations of autoimmune diseases.

Ronco P, Debiec H.

Clin Kidney J. 2012 Apr;5(2):91-93. doi: 10.1093/ckj/sfs016. Epub 2012 Mar 15. No abstract available.

43.

Pathogenesis of membranous nephropathy: recent advances and future challenges.

Ronco P, Debiec H.

Nat Rev Nephrol. 2012 Feb 28;8(4):203-13. doi: 10.1038/nrneph.2012.35. Review.

PMID:
22371247
44.

[Idiopathic and secondary membranous nephropathies].

Ronco P, Debiec H.

Presse Med. 2012 Mar;41(3 Pt 1):290-7. doi: 10.1016/j.lpm.2011.11.004. Epub 2011 Dec 28. Review. French.

PMID:
22208961
45.

Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy.

Ribeiro A, Wörnle M, Motamedi N, Anders HJ, Gröne EF, Nitschko H, Kurktschiev P, Debiec H, Kretzler M, Cohen CD, Gröne HJ, Schlöndorff D, Schmid H.

Kidney Int. 2012 Jan;81(1):100-11. doi: 10.1038/ki.2011.311. Epub 2011 Sep 14.

46.

Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy.

Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, Mousson C, Ronco P.

Am J Transplant. 2011 Oct;11(10):2144-52. doi: 10.1111/j.1600-6143.2011.03643.x. Epub 2011 Aug 9.

47.

Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy.

Debiec H, Ronco P.

Nat Rev Nephrol. 2011 Aug 9;7(9):496-8. doi: 10.1038/nrneph.2011.106. No abstract available.

PMID:
21826078
48.

Early-childhood membranous nephropathy due to cationic bovine serum albumin.

Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, Ronco P.

N Engl J Med. 2011 Jun 2;364(22):2101-10. doi: 10.1056/NEJMoa1013792. Erratum in: N Engl J Med. 2011 Aug 4;365(5):477. N Engl J Med. 2014 Feb 27;370(9):886.

49.

Advances in membranous nephropathy: success stories of a long journey.

Ronco P, Debiec H.

Clin Exp Pharmacol Physiol. 2011 Jul;38(7):460-6. doi: 10.1111/j.1440-1681.2011.05506.x. Review.

PMID:
21388432
50.

PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.

Debiec H, Ronco P.

N Engl J Med. 2011 Feb 17;364(7):689-90. doi: 10.1056/NEJMc1011678. No abstract available.

PMID:
21323563

Supplemental Content

Loading ...
Support Center